Bavarian Nordic (BAVA.CO) Stock Analysis & AI Equity Report

Biotechnology DKK Explore free reports

Bavarian Nordic (BAVA.CO) overview

Bavarian Nordic (BAVA.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, Bavarian Nordic reported revenue of DKK 6,171m and operating profit of DKK 921m; the year-end share price was 190.85 DKK and market capitalisation was DKK 14,892m. Bavarian Nordic is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bavarian Nordic's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueDKK 12,870mFY 2025
Share price190.85 DKKFY 2025 year end
RevenueDKK 6,171mFY 2025
Operating profitDKK 921mFY 2025
Net earningsDKK 1,375mFY 2025
Market capitalisationDKK 14,892mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About Bavarian Nordic

Bavarian Nordic is a vaccines company focused on researching, developing, manufacturing, and commercializing preventive vaccines. Its portfolio includes travel vaccines such as rabies, tick-borne encephalitis, cholera, typhoid, and chikungunya vaccines, as well as smallpox and mpox vaccines supplied to governments and international organizations for public health preparedness.

Generate the Bavarian Nordic report

Bavarian Nordic is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Bavarian Nordic and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Bavarian Nordic

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.